Patent litigation is sometimes described as a duel. The metaphor is wrong. The disputes that have shaped modern intellectual property law are better understood as wars: campaigns fought across many fronts at once, in courts on three or four continents, before administrative tribunals, at the International Trade Commission, and inside the offices of antitrust regulators—all simultaneously, all feeding into one set of negotiations. The combatants are rarely fighting over a single patent or a single product. They are fighting over the architecture of an entire industry, over who controls a technology standard, over which company will dominate a market for the next decade, and over how the global rules of innovation should be written.

This article studies eight of the most instructive of these conflicts. Some are famous—the smartphone wars between Apple and Samsung produced a billion-dollar verdict and a unanimous Supreme Court opinion. Some are quieter but more important to the way technology is actually licensed today, like the long campaign over standard-essential patents and the obligation to license them on fair, reasonable, and non-discriminatory terms. And some have reached into life itself, as in the multibillion-dollar wall of patents that protected the world's best-selling drug, the Supreme Court's reshaping of what it takes to claim a class of antibodies, and the fight over who invented the gene-editing tool that is rewriting medicine.

For each case study, this article does four things in plain language: it explains what happened, identifies the legal issues at stake, describes the outcome, and draws out the strategic takeaway for companies and counsel. Throughout, terms of art are defined the first time they appear, and invented examples (clearly labeled with names like "Acme Corp." or "Borealis Labs") are used to illustrate doctrines that might otherwise stay abstract. The goal is that a judge, a seasoned patent litigator, and an interested non-lawyer can all read the same paragraph and take away the same lesson.

These case studies are best read alongside the firm's companion pieces on the mechanics of cross-border practice—our overview of global patent litigation strategies, our deep dive on standard-essential patents and FRAND licensing in 5G and IoT, our comprehensive guide to patent infringement litigation, and our analysis of the LKQ decision and its reshaping of design patent obviousness. For readers new to the underlying doctrine, our plain-English guide to patent basics and our explainer on what constitutes patent infringement provide the foundation on which the analysis below builds.

A Short Primer on the Battlefield

Before turning to the cases, it helps to understand the terrain. A patent is a government-granted right to exclude others from making, using, selling, or importing an invention for a limited time—generally twenty years from the earliest filing date for a utility patent in the United States. Patents come in flavors. A utility patent protects how something works—a chemical compound, a wireless transmission method, a software algorithm. A design patent protects how something looks—the ornamental appearance of an article of manufacture, like the rounded-corner rectangle of a phone, and runs for fifteen years from grant. The distinction will matter enormously in the Apple-Samsung story. (Our companion pieces on utility patent basics and the intersection of design and utility patents develop the line between them.)

Several recurring institutions appear across the case studies. The International Trade Commission (ITC) is a U.S. federal agency that can, under Section 337 of the Tariff Act, 19 U.S.C. § 1337, bar infringing products from being imported into the United States. An ITC exclusion order functions as a powerful injunction because it shuts a product out of the U.S. market entirely, and crucially the ITC does not apply the Supreme Court's restrictive four-factor injunction test from eBay Inc. v. MercExchange, L.L.C., 547 U.S. 388 (2006). For products manufactured abroad—which is to say most consumer electronics—an exclusion order is therefore often more fearsome than a district-court injunction. The Patent Trial and Appeal Board (PTAB) is the tribunal within the U.S. Patent and Trademark Office (USPTO) where accused infringers can challenge the validity of patents through inter partes review, often in parallel with district-court litigation. In Europe, the European Patent Office (EPO) grants patents that then split into a bundle of national rights enforced country by country, a fragmentation that one Practical Law commentary aptly described as a "Gordian knot"—a system with "innumerable strands" of national procedure "tied together by threads of EU law"—and the new Unified Patent Court (UPC), which opened its doors in June 2023, now offers a genuinely pan-European forum that can grant injunctions spanning the participating member states. Finally, standard-setting organizations (SSOs) like ETSI and IEEE develop the technical standards—4G, 5G, Wi-Fi, video codecs—that let devices from different makers interoperate, and they require contributors to license their standard-essential patents (SEPs) on fair, reasonable, and non-discriminatory (FRAND) terms (the U.S. variant is often abbreviated RAND). Almost every modern patent war touches at least one of these institutions, and the sophisticated ones touch all of them at once.

Case Study 1: Apple v. Samsung and the Meaning of Section 289

What Happened

In April 2011, Apple sued Samsung in the U.S. District Court for the Northern District of California, alleging that Samsung's Galaxy smartphones and tablets copied the iPhone's distinctive look and infringed both utility patents and design patents covering features such as the black rectangular face with rounded corners, the surrounding bezel, and the grid of colorful rounded icons. Samsung counterclaimed. What began in California metastasized into a global campaign spanning courts in Germany, the United Kingdom, the Netherlands, Australia, Japan, and South Korea, with each side seeking injunctions, damages, and import bans wherever it could find a sympathetic forum.

The U.S. case produced the headline. In August 2012, a Northern District of California jury awarded Apple just over one billion dollars. After retrials and appeals trimmed and reshaped that figure, one issue rose to the Supreme Court of the United States, and it was a narrow but profound question about how to calculate damages for design patent infringement.

The Legal Issue

The dispute turned on 35 U.S.C. § 289, a damages statute unique to design patents. Section 289 provides that anyone who applies a patented design "to any article of manufacture" shall be liable to the patent owner "to the extent of his total profit." Read literally and applied to a smartphone, that language is explosive. The lower courts had instructed the jury that the "article of manufacture" was the entire phone, so Apple was entitled to all of Samsung's profits on the infringing phones—even though the patented designs covered only the exterior shell and the screen graphics, not the processor, the antenna, the battery, the operating system, or the thousands of other components that make a phone valuable. The result was that Samsung owed its entire profit on a multi-component device for infringing designs that covered only its surface.

The question for the Supreme Court was deceptively simple: when an infringing product has many components, is the "article of manufacture" necessarily the whole end product sold to consumers, or can it be just the component to which the patented design was applied?

The Outcome

In Samsung Electronics Co. v. Apple Inc., 580 U.S. 53 (2016), a unanimous Supreme Court, in an opinion by Justice Sotomayor, held that the "article of manufacture" can be either the entire product or only a component of it. The Court reasoned from ordinary meaning: an "article of manufacture" is simply a thing made by hand or machine, and a component of a product is itself a thing made by hand or machine. Nothing in the statute compelled treating the consumer-facing end product as the only permissible unit. The Court declined, however, to set out a test for how to identify the relevant article of manufacture in any given case, leaving that to be worked out on remand. The U.S. Solicitor General had proposed a four-factor approach—looking at the scope of the claimed design, how prominent the design is within the product as a whole, whether the design is conceptually distinct from the product, and the physical relationship between the patented design and the rest of the product—and the Federal Circuit and district courts have largely gravitated toward that framework. The case itself ultimately settled in 2018 after a further jury trial that, applying the new standard, awarded Apple a figure (roughly $539 million) well above what Samsung had argued for but tethered to a more searching component analysis.

The Strategic Takeaway

The doctrinal lesson is that Samsung v. Apple defused what had looked like a nuclear option in design patent litigation. Before the decision, a design patent on a minor visual element of a complex product threatened to capture the total profit on the whole product—a remedy wildly disproportionate to the contribution of the design. After the decision, defendants can argue that the relevant "article of manufacture" is a narrower component, dramatically shrinking the available recovery.

The decision also reframed how design patents should be drafted and read, and the Federal Circuit's later decision in Curver Luxembourg, SARL v. Home Expressions Inc., 938 F.3d 1334 (Fed. Cir. 2019), drove the point home from the other direction. There, a design patent claimed an ornamental "Y" pattern "for a chair," but the figures depicted only the pattern, not any chair. The Federal Circuit held, as a matter of first impression, that the claim language identifying the article of manufacture could limit the scope of the patent even where the figures did not depict that article—so the patent did not reach the same pattern applied to a basket. The practical lesson for prosecutors is that how an applicant names and depicts the article of manufacture is not a formality; it defines both the scope of the right and, after Samsung, the universe of profits potentially recoverable under Section 289.

The more durable strategic lesson is about leverage and scope. Design patents remain potent precisely because Section 289 offers a profits remedy that is unavailable for utility patents, where damages are measured by reasonable royalty or lost profits under 35 U.S.C. § 284. A company building a consumer product should treat design protection as a first-class part of its IP portfolio, not an afterthought—and an accused infringer should immediately scrutinize whether the asserted design reads on the entire product or only a part. This is also why the Federal Circuit's en banc reworking of the standard for design patent obviousness in the LKQ case matters so much: as we explain in our analysis of the LKQ decision, the validity of design patents is now easier to attack, which changes the risk calculus on both sides. For practitioners weighing how design and utility rights interact, the firm's discussion of concurrent design and utility patent protection and our overview of design patents versus trade dress for product configurations are useful companions.

There is also a global lesson buried in the Apple-Samsung saga, and it is the central theme of this article: outcomes diverged wildly by jurisdiction. Apple won big in California; the United Kingdom and the Netherlands found no infringement of Apple's design rights and at one point ordered Apple to publish a notice saying so; Japan and South Korea split or favored Samsung. No single forum's result controlled the others. Multi-jurisdictional patent disputes are not a single case litigated in many places—they are many independent cases whose only unifying force is the eventual global settlement.

Consider how this plays out in practice with an invented illustration. Hypothetical: Suppose Acme Corp. holds a design patent on the ornamental shape of a fitness tracker and sues its rival Borealis Labs in the United States, Germany, and the United Kingdom at once. Acme might win in Germany, where courts grant injunctions relatively readily and bifurcate validity from infringement so that an injunction can issue before validity is fully tested; lose in the UK, where a court finds the registered design not infringed because an informed user would perceive a different overall impression; and obtain only modest damages in the United States after a court applies the Samsung factors and limits the relevant "article of manufacture" to the tracker's housing rather than the entire device. Acme now holds a German injunction it can use as leverage, a UK loss it must contain, and a U.S. damages number that is real but smaller than hoped. None of these results binds the others, but together they set the contours of the settlement Acme and Borealis will eventually reach. The lesson for both sides is that a global patent war is won or lost in the aggregate, and counsel must manage the portfolio of proceedings as a single campaign rather than scoring each case in isolation.

Case Study 2: The SEP-FRAND Wars—Nokia, Qualcomm, and Apple

What Happened

While Apple and Samsung fought over how phones looked, a deeper and more consequential war was being fought over how phones talk. Every smartphone implements cellular and wireless standards—GSM, UMTS, LTE, 5G, Wi-Fi—and those standards are built on thousands of patented inventions. The companies that contributed the foundational technology, including Nokia and Qualcomm, hold enormous portfolios of standard-essential patents. The companies that build the devices, including Apple, must use those standards to make a working phone. The two sides are locked together: the implementer cannot avoid the standard, and the SEP holder has promised the standard-setting body to license on FRAND terms. The entire dispute is about what "fair, reasonable, and non-discriminatory" means in dollars.

Nokia sued Apple in 2009, asserting GSM and wireless patents against the iPhone in the District of Delaware, the ITC, and German courts, and the parties settled in 2011 with Apple paying ongoing royalties (the two would later renew hostilities and settle again in 2017). The Qualcomm conflict was larger and angrier. Beginning in 2017, Apple and Qualcomm fought across the United States, China, Germany, and the United Kingdom, with Apple alleging that Qualcomm's "no license, no chips" policy—refusing to sell baseband chips unless the customer also took a patent license—was an unlawful abuse of its standard-essential position, and Qualcomm counter-asserting patents and winning preliminary injunctions on certain iPhone models in China and Germany. In parallel, the U.S. Federal Trade Commission sued Qualcomm on antitrust grounds.

The Legal Issues

Two doctrines collide in SEP cases. The first is patent holdup, the concern, articulated by U.S. antitrust authorities during the Obama administration, that because creating a standard requires the SSO to choose among competing technologies and the industry then becomes locked into that choice—especially where there are strong network effects and each generation of technology builds on the last—the SEP holder gains market power it did not have before the standard was set, and can extract royalties far above the patent's true economic contribution. As one Practical Law commentary on SEPs frames it, the patent holder can then "exploit this market power by acting opportunistically to charge licensees more than they would have been willing to pay for the technology before the standard was set," with the threat of an injunction supplying the leverage. The second is patent holdout (or "reverse holdup"), the concern, emphasized by later Department of Justice leadership in the "New Madison" approach announced by Assistant Attorney General Makan Delrahim in 2018, that implementers will simply refuse to negotiate in good faith, forcing the patent holder to litigate or forgo revenue entirely. Whether a FRAND breach is merely a contract problem or also an antitrust violation under Section 2 of the Sherman Act became a central battleground.

The two enforcement postures could hardly have been more different. During the Obama administration, the FTC and DOJ treated some SEP conduct as a Sherman Act or FTC Act problem and acted on it, extracting consent orders constraining injunction-seeking by SEP holders—for example, in the matters of Robert Bosch GmbH (FTC Docket No. C-4377) and Motorola Mobility LLC and Google Inc. (FTC File No. 121-0120), and earlier in Rambus and Negotiated Data Solutions, where nondisclosure or post-acquisition repudiation of FRAND commitments drew enforcement attention. The "New Madison" DOJ, by contrast, took the view that a FRAND commitment "should not be transformed into a compulsory licensing scheme," that breaches of FRAND commitments belong in contract law, and that patent holdup is generally not an antitrust problem at all.

The Qualcomm antitrust litigation tested exactly this. The Northern District of California initially held that Qualcomm's licensing practices violated the Sherman Act and the FTC Act and imposed a sweeping remedy requiring Qualcomm to renegotiate its licenses. But in FTC v. Qualcomm Inc., 969 F.3d 974 (9th Cir. 2020), the Ninth Circuit reversed, holding that Qualcomm's conduct, however aggressive, was largely "hypercompetitive, not anticompetitive," and that a breach of a FRAND commitment is generally a matter for contract and patent law rather than antitrust law. The decision marked a significant retreat from the holdup theory in U.S. antitrust enforcement and left the regulation of FRAND conduct largely to private contract litigation and to foreign authorities.

The Outcome

The private Apple-Qualcomm war ended abruptly. On the very day opening statements began in their San Diego trial in April 2019, the companies announced a global settlement: Apple paid Qualcomm a lump sum (reportedly billions of dollars), entered a multiyear license and a chip supply agreement, and dropped all litigation worldwide. The settlement is the perfect illustration of how these wars actually end—not with a judicial pronouncement of the "correct" FRAND rate, but with a negotiated peace reached once both sides have absorbed enough litigation risk that certainty becomes more valuable than continued fighting. Notably, the deal closed before the Ninth Circuit decided the parallel FTC case in Qualcomm's favor; neither side knew, when it settled, how the antitrust question would come out.

The Strategic Takeaway

The SEP-FRAND wars teach that injunctive leverage is the prize. An SEP holder who can credibly threaten to exclude a product—via an ITC exclusion order or a foreign injunction in a jurisdiction like Germany or China that grants injunctions more readily than U.S. courts do under eBay—holds enormous bargaining power, because no device maker can ship a phone that cannot connect to the network. Conversely, the FRAND commitment is the implementer's shield: it is a promise, enforceable as a third-party-beneficiary contract, that the SEP holder will not wield that exclusionary power to extract supra-competitive royalties. The litigation is the costly process by which the parties discover where, between those poles, the rate actually lies.

For counsel, the practical guidance is to fight on the forums that maximize your structural advantage. SEP holders gravitate toward injunction-friendly jurisdictions, the ITC, and now the UPC; implementers gravitate toward U.S. district courts, FRAND rate-setting proceedings, and antitrust regulators. There is also a documentation lesson that the Qualcomm fight underscores, and that the U.S. antitrust retreat makes more important rather than less: because the question of FRAND compliance has migrated from antitrust enforcers to private contract and patent courts, and because those courts increasingly decide cases on whether each side negotiated in good faith, the negotiation record itself becomes the decisive evidence. An SEP holder should be able to show that it identified the essential patents, explained its royalty methodology, and made a concrete offer; an implementer should be able to show that it engaged promptly, asked substantive questions, and made or sought a genuine counter-offer. Parties that treat licensing negotiations as a paper trail to be built—rather than mere preliminaries to litigation—enter any eventual courtroom with a decisive advantage. The firm's dedicated treatment of standard-essential patents and FRAND licensing in 5G and IoT develops these negotiation dynamics in depth; our guidance on drafting an effective patent notice letter and on how to license your patent from valuation to term sheet addresses the documentary discipline that wins these cases; and our overview of global patent litigation strategies explains how to coordinate parallel proceedings so that a win in one forum reinforces rather than undercuts your position in another.

Case Study 3: Huawei v. ZTE and the CJEU's FRAND Framework

What Happened

The SEP wars were not confined to the United States. In Europe, the question of when an SEP holder could obtain an injunction against a willing licensee came to a head in a German referral to the Court of Justice of the European Union (CJEU). Huawei held a patent essential to the 4G/LTE standard and had committed to ETSI, the relevant standard-setting organization, to license it on FRAND terms. Huawei sued ZTE in Germany for an injunction. ZTE argued that seeking an injunction against a company willing to take a FRAND license was itself an abuse of a dominant position under Article 102 of the Treaty on the Functioning of the European Union (TFEU)—the EU's prohibition on abuse of market dominance.

The Legal Issue

The tension is the same one running through the entire SEP story, but framed through EU competition law. A patent ordinarily includes the right to seek an injunction. But an SEP holder has voluntarily promised to license on FRAND terms, and it holds market power conferred by the standard. May it nonetheless ask a court to exclude a competitor's product, or does doing so abuse its dominance? The CJEU's task was to reconcile the patent holder's right to judicial protection of its property with competition law's concern about exploiting standard-conferred dominance—the European mirror image of the holdup/holdout debate that the U.S. agencies were fighting over at the same time.

The Outcome

In Huawei Technologies Co. Ltd v. ZTE Corp., Case C-170/13 (CJEU, 16 July 2015), the Court constructed a step-by-step negotiation protocol—a roadmap that both sides must follow before an injunction is appropriate. In essence: before suing, the SEP holder must alert the implementer to the infringement, identifying the patent and how it is infringed. If the implementer expresses willingness to take a FRAND license, the SEP holder must make a specific written FRAND offer, stating the royalty and how it is calculated. The implementer must then respond diligently and in good faith, and if it rejects the offer it must promptly make a FRAND counter-offer. If the implementer continues using the patent without agreement, it should provide appropriate security (for example, a bank guarantee) and render an account of its use. An SEP holder that follows these steps and is met by an unwilling, dilatory licensee may seek an injunction without abusing its dominance; an SEP holder that skips the steps and sues a genuinely willing licensee risks an Article 102 violation.

The Strategic Takeaway

Huawei v. ZTE converted an open-ended antitrust standard into a procedural choreography, and the practical lesson is that in Europe, conduct during negotiation determines the remedy. The "willing licensee" and "willing licensor" are no longer rhetorical labels—they are tested against a concrete sequence of notices, offers, and counter-offers. An SEP holder that wants the leverage of an injunction must build a documented FRAND offer and a clean negotiation record before filing suit. An implementer that wants to keep the injunction off the table must respond promptly, engage seriously, and put up security; the worst thing it can do is stall, because the framework treats stalling as evidence of unwillingness that unlocks the injunction.

Hypothetical: Imagine Northstar Communications, which holds an LTE-essential patent, emails Cyrus Devices a single line—"you infringe our portfolio, pay up"—and sues for an injunction in a UPC division three weeks later, never having identified a patent number or quoted a rate. Even if Cyrus genuinely infringes, Northstar has skipped the Huawei v. ZTE steps and exposed itself to an Article 102 defense, and a court may refuse the injunction. Now reverse it: Northstar sends a claim chart, a specific royalty, and the math behind it, and Cyrus responds with months of silence followed by vague requests for "more information" but no counter-offer and no security. Cyrus has behaved like an unwilling licensee, and the injunction is back on the table. The doctrine rewards the side that builds the better paper trail.

The decision also illustrates a structural feature of European patent litigation. As the Practical Law commentary on the "Gordian knot" of European patent practice observes, the European system historically fragmented into national rights enforced country by country, with no single forum binding all of Europe. Huawei v. ZTE gave national courts—above all the patent-heavy German courts—a common framework, harmonizing the FRAND injunction analysis across the EU even before the Unified Patent Court arrived in 2023 to offer a genuinely pan-European forum whose injunctions can reach every participating member state at once. For an SEP holder, that pan-European reach turns the UPC into a holdup-grade weapon; for an implementer, it raises the stakes of getting the Huawei v. ZTE dance right.

Case Study 4: Unwired Planet v. Huawei and the Global FRAND Rate

What Happened

If Huawei v. ZTE was about when an injunction is available, the next great SEP case was about what a court can decide. Unwired Planet, a patent licensing company that had acquired a portfolio of cellular SEPs originally developed by Ericsson, sued Huawei in the United Kingdom for infringing patents it had committed to license on FRAND terms. The technical patents were litigated and some were found valid and infringed. Then came the radical move: the English High Court did not merely decide whether the UK patents were infringed. It undertook to determine the FRAND royalty rate for a global license to Unwired Planet's entire portfolio, and it held that if Huawei refused to take that worldwide license, it would be enjoined from selling in the United Kingdom.

The Legal Issue

The question was jurisdictional and almost philosophical. A UK court's patents cover the United Kingdom; it cannot adjudicate infringement of a Chinese or German patent. So can a UK court nonetheless set the terms of a worldwide license—effectively dictating what Huawei must pay for Unwired Planet's patents in every country—and condition access to the UK market on accepting those global terms? Huawei argued this was an extraterritorial overreach: the UK court was arrogating to itself the role of a global rate-setter for patents it had no power to adjudicate.

The Outcome

In Unwired Planet International Ltd v. Huawei Technologies (UK) Co. Ltd [2020] UKSC 37, the UK Supreme Court unanimously affirmed that English courts may indeed determine the terms of a global FRAND license and may grant an injunction against UK sales if the implementer refuses to enter that license. The Court reasoned that because real-world parties in the industry license SEP portfolios on a worldwide basis—nobody negotiates a separate license country by country—a FRAND determination that ignored that commercial reality would be artificial. The FRAND undertaking, given to ETSI, was itself international in character, and the English court was simply giving it practical effect. The injunction was not extraterritorial: it bound only UK sales. But the only way to avoid it was to accept a global license.

The Strategic Takeaway

Unwired Planet transformed the United Kingdom into one of the most attractive forums on earth for an SEP holder, because a UK judgment could effectively resolve a worldwide licensing dispute. The practical lesson is about forum selection as strategy: a patentee that wins the race to a court willing to set global terms can, in a single proceeding, achieve what would otherwise require parallel litigation in a dozen countries. The decision triggered a forum-selection arms race. SEP holders rushed to UK and (later) other courts willing to set global rates, while implementers responded by seeking anti-suit injunctions—orders from a court in one country (notably Chinese courts, and in some matters U.S. courts) forbidding a party from pursuing or enforcing litigation abroad—which in turn provoked anti-anti-suit injunctions from the courts whose proceedings were threatened, and occasionally a further round still. Chinese courts in particular signaled their own willingness to set global FRAND rates (as in OPPO v. Sharp and related matters), so that the question is no longer whether a national court will set a worldwide rate but which national court gets there first.

The result is a high-stakes jurisdictional chess match in which the first mover and the choice of forum can determine the economics of a global portfolio. Any company with a meaningful SEP position, on either side, must now treat forum selection not as a procedural detail but as the central strategic decision of the entire dispute. Our broader treatment of cross-border coordination in global patent litigation strategies walks through how to sequence filings, when to seek or resist an anti-suit injunction, and how to keep parallel proceedings from working at cross-purposes; and for disputes that reach into China specifically, our practitioner's guide to serving defendants in China under the Hague Service Convention addresses the procedural mechanics that an anti-suit campaign turns on.

Case Study 5: The Smartphone NPE Wars

What Happened

Not every patent war is fought between manufacturers. A defining feature of the smartphone era was the rise of the non-practicing entity (NPE)—a company that owns patents but makes no products, earning its return entirely by licensing and litigation. NPEs are not all alike. As Practical Law explains, NPEs "include all patent intermediaries that do not engage in business operations, including research entities and universities"; what distinguishes the aggressive subset—the patent assertion entity (PAE), colloquially the "patent troll"—is a business model focused on "buying and asserting patents against operating companies that are allegedly already using the technology, rather than contributing to the development or transfer of technologies." Some NPEs are universities or failed startups monetizing genuine inventions; others are litigation vehicles that acquired portfolios specifically to extract settlements. During the smartphone boom, PAE activity exploded—by 2012 PAEs accounted for the majority of all patent suits filed in the United States—and thousands of suits targeted device makers, app developers, and even retailers and end users over features ranging from scroll bounce to podcasting to scanning documents to email. A 2013 White House report (Patent Assertion and U.S. Innovation) estimated the cost of this activity in the tens of billions of dollars and described PAEs as imposing an "economic 'dead weight loss'" on innovation.

The structural dynamic is what makes the NPE war distinctive. Because an NPE sells no products, it is largely immune to the most common defensive weapon in inter-manufacturer disputes—the counterclaim. When Apple sues Samsung, Samsung sues back; mutual exposure pushes both toward a cross-license. But an NPE has no products to enjoin and no business to disrupt, so the defendant has no counter-leverage and faces an asymmetric fight: the cost of defending a patent case through trial often exceeds the cost of an early settlement, which is precisely the economic pressure that nuisance-value suits are designed to exploit. PAEs sharpen that asymmetry by litigating through shell companies that hide the real party in interest, making them, as the White House report put it, "difficult to defend against and largely invulnerable to counterclaims." The firm's stand-alone treatment of addressing the patent assertion entity problem develops the policy debate in more detail.

The Legal Issues and the Tools That Reshaped the War

Three legal developments dramatically reshaped the NPE battlefield, and each is a strategic lesson in itself.

First, eBay Inc. v. MercExchange, L.L.C., 547 U.S. 388 (2006) eliminated the near-automatic injunction in U.S. patent cases. The Supreme Court held that a patentee must satisfy the traditional four-factor equitable test—irreparable harm, inadequacy of money damages, the balance of hardships, and the public interest—to obtain an injunction. Because an NPE that does not compete in the market usually cannot show irreparable harm, eBay stripped NPEs of their most fearsome weapon in district court and pushed many toward the ITC, which does not apply eBay, or toward damages-only litigation.

Second, the Leahy-Smith America Invents Act of 2011 created inter partes review (IPR) before the PTAB, giving accused infringers a faster, cheaper administrative path to invalidate weak patents under 35 U.S.C. §§ 311-319. An NPE asserting a dubious patent now faces a real risk that the patent itself will be canceled, often before the district-court case reaches trial (because courts frequently stay litigation pending IPR). The validity of the asserted patent—not just infringement—became a front-and-center battleground, and our comprehensive guide to patent infringement litigation explains how district-court and PTAB proceedings now run in tandem.

Third, Alice Corp. v. CLS Bank International, 573 U.S. 208 (2014) made it far easier to invalidate abstract software and business-method patents at the pleading stage under 35 U.S.C. § 101. Many NPE portfolios consisted of broadly worded software patents that suddenly became vulnerable to early dismissal on a motion under Rule 12. As the firm explains in its analysis of patent eligibility after Alice, the decision reset the value of large swaths of software patents overnight.

To these judicial and administrative tools Congress and the courts added procedural reforms. The fee-shifting decisions in Octane Fitness, LLC v. ICON Health & Fitness, Inc., 572 U.S. 545 (2014), and Highmark Inc. v. Allcare Health Management System, Inc., 572 U.S. 559 (2014), made it materially easier for a prevailing defendant to recover attorneys' fees in an "exceptional" case under 35 U.S.C. § 285—exactly the fee-shifting medicine the 2013 White House report had recommended as a deterrent to weak assertions. And venue reform arrived with TC Heartland LLC v. Kraft Foods Group Brands LLC, 581 U.S. 258 (2017), which curtailed the practice of filing patent suits in plaintiff-friendly districts (above all the Eastern District of Texas) by holding that a domestic corporation "resides," for venue purposes, only in its state of incorporation.

The Outcome and the Strategic Takeaway

The combined effect of eBay, IPR, Alice, fee-shifting, and venue reform was to deflate the most abusive NPE litigation while leaving legitimate patent licensing intact. Defendants learned that the best response to an NPE is rarely a quick settlement and rarely a counterclaim that has nowhere to land. It is a coordinated attack on the patent itself: file IPRs to invalidate the asserted claims, move early under Alice if the patent is software, challenge venue under TC Heartland, hold the threat of a fee award over a marginal plaintiff, and join defense coalitions or patent-defense aggregators that share the cost of fighting common assertors. The strategic lesson of the NPE wars is that when you cannot counterattack on products, you counterattack on validity—and you do it collectively to neutralize the asymmetry that makes NPE litigation profitable in the first place. For companies trying to avoid the fight altogether, our guidance on conducting freedom-to-operate analysis for new products and on responding to a patent notice letter addresses the clearance and triage work that keeps an NPE letter from ripening into a lawsuit.

Case Study 6: The Biopharma Patent Cliff and the Humira Thicket

What Happened

The patent wars are not only about phones. In pharmaceuticals, the central event in any blockbuster drug's life is the patent cliff: the moment when the patents protecting a product expire and lower-priced competitors flood in, collapsing the originator's revenue. For small-molecule drugs (ordinary chemical pills), the generic version arrives through the Hatch-Waxman pathway, with its Orange Book patent listings and Paragraph IV certifications. For biologics—large, complex molecules made in living cells, like antibodies—the competitor is a biosimilar, a product that is "highly similar" to the reference biologic with "no clinically meaningful differences," approved through the abbreviated pathway Congress created in the Biologics Price Competition and Innovation Act of 2009 (BPCIA), codified at 42 U.S.C. § 262(k).

The defining example is AbbVie's Humira (adalimumab), an anti-inflammatory antibody used for rheumatoid arthritis, Crohn's disease, psoriasis, and more, and for years the best-selling drug in the world, generating roughly twenty billion dollars in annual revenue at its peak. Humira's core composition-of-matter patent expired in the United States in 2016. Ordinary economics predicted a cliff. Instead, biosimilar competition did not arrive in the U.S. market until 2023. AbbVie had built what observers call a patent thicket—a dense, overlapping web of more than one hundred patents covering not just the molecule but methods of manufacturing, formulations, dosing regimens, and treatment of particular conditions—surrounding the product so thoroughly that any biosimilar maker faced the prospect of litigating dozens of patents before it could safely launch.

The Legal Issues

Two legal structures made the thicket possible. The first is the patent system's tolerance for continuation and improvement patents: an originator can keep filing patents on incremental innovations—a new formulation, a new manufacturing step, a new indication—each with its own term, so that the wall of protection extends years beyond the original molecule's expiration. The second is the BPCIA's litigation framework, the so-called patent dance of 42 U.S.C. § 262(l), an elaborate, statutorily choreographed exchange of patent and manufacturing information between the biosimilar applicant and the reference product sponsor that is meant to channel patent disputes into an orderly pre-launch process. The Supreme Court addressed the dance's mechanics in Sandoz Inc. v. Amgen Inc., 582 U.S. 1 (2017), holding that the statute's information-exchange steps are not enforceable by federal injunction and that a biosimilar applicant may give its notice of commercial marketing before FDA licensure. Layered on top is the BPCIA's twelve-year regulatory exclusivity for the reference biologic, independent of patents. The combination of a thicket of patents and a structured dispute procedure gave AbbVie a powerful position from which to negotiate.

The Outcome

AbbVie did not generally litigate the thicket to judgment against the biosimilar makers. It used the thicket as leverage to negotiate. Beginning around 2017, AbbVie entered a series of settlement agreements with biosimilar manufacturers—Amgen, Samsung Bioepis, Sandoz, and others—under which each agreed to delay its U.S. launch until 2023 in exchange for an earlier, royalty-bearing entry than full litigation might have produced. The practical result was that Humira enjoyed roughly seven additional years of effective monopoly in the United States beyond the expiration of its core patent, even as biosimilars launched in Europe years earlier. When competition finally arrived in 2023, it arrived all at once, as the staggered settlements opened the floodgates.

The Strategic Takeaway

The Humira story is the canonical lesson in lifecycle management—the deliberate strategy of extending a product's commercial exclusivity through a portfolio of layered patents and regulatory exclusivities rather than relying on a single core patent. For an originator, the takeaway is that the patent cliff is not a fixed date; it is a position that can be defended and extended through disciplined, long-horizon filing strategy. For a biosimilar challenger, the lesson is that beating the molecule patent is only the beginning—the real obstacle is the thicket, and the realistic path to market often runs through a negotiated entry date rather than a clean litigation victory.

The Humira episode also drew intense policy scrutiny, with regulators and legislators in the United States debating whether thickets and reverse-payment-adjacent settlements abuse the patent system to forestall competition. That debate sits squarely on top of antitrust doctrine: in FTC v. Actavis, Inc., 570 U.S. 136 (2013), the Supreme Court held that a "pay-for-delay" settlement—in which a brand pays a would-be competitor to stay out of the market—can violate the antitrust laws and is judged under the rule of reason, eliminating the old assumption that anything within the nominal "scope of the patent" was immune. Companies orchestrating staggered biosimilar settlements must therefore weigh antitrust exposure alongside patent strategy, structuring entry dates and any value transfers with Actavis in mind. The firm's overview of biosimilars and the BPCIA pathway and our discussion of conducting freedom-to-operate analysis for new products develop the clearance and risk-assessment work that a biosimilar entrant must do before it ever files.

Case Study 7: Amgen v. Sanofi and the Enablement Requirement

What Happened

If the Humira thicket shows how patents can be used to extend protection, Amgen Inc. v. Sanofi shows how they can collapse when claimed too broadly. The dispute concerned cholesterol-lowering drugs that work by targeting a protein called PCSK9. Antibodies that bind PCSK9 prevent it from degrading the receptors that clear "bad" LDL cholesterol from the blood, so blocking PCSK9 lowers cholesterol. Amgen developed one such antibody (Repatha); Sanofi and Regeneron developed a different one (Praluent). The two antibodies had different amino acid sequences, but Amgen had obtained patents claiming not a specific antibody but an entire genus—the whole class of antibodies defined by their function: any antibody that binds to particular amino acids on the PCSK9 protein and blocks its activity. Amgen argued that Sanofi's structurally distinct antibody fell within that functional class and infringed. Sanofi argued the functional claims were invalid.

The Legal Issue

The case turned on the enablement requirement of 35 U.S.C. § 112(a), which demands that a patent's written description teach a person skilled in the art how to make and use the full scope of the claimed invention without undue experimentation. The bargain at the heart of patent law is disclosure for exclusivity: you may claim what you have enabled the public to practice, and no more. Amgen's patents disclosed the amino acid sequences of twenty-six specific antibodies and offered two general methods—a "roadmap" and "conservative substitution"—for finding others. But the functional claims potentially covered millions of antibodies that bind the same region. The question was whether disclosing twenty-six examples and a research strategy enables a person of skill to make the entire genus, or whether it instead invites a vast program of trial-and-error experimentation to hunt down the rest.

The Outcome

In Amgen Inc. v. Sanofi, 598 U.S. 594 (2023), a unanimous Supreme Court, in an opinion by Justice Gorsuch, held Amgen's broad functional claims invalid for lack of enablement. The Court reaffirmed that the more a patent claims, the more it must enable: "If a patent claims an entire class of processes, machines, manufactures, or compositions of matter, the patent's specification must enable a person skilled in the art to make and use the entire class." A patentee may rely on a general quality or a disclosed example only if that disclosure genuinely teaches how to reach the full scope without forcing others to engage in painstaking experimentation. Amgen's roadmap and substitution methods, the Court found, amounted to little more than an invitation to "go forth and try"—a research assignment, not an enabling disclosure of the millions of antibodies the claims swept in. The decision drew an explicit line from nineteenth-century precedents like O'Reilly v. Morse, 56 U.S. (15 How.) 62 (1854) (rejecting Samuel Morse's claim to electromagnetism for any printing at a distance) and The Incandescent Lamp Patent, 159 U.S. 465 (1895) (rejecting a claim to all fibrous carbon filaments), through to modern antibody claims.

The Strategic Takeaway

Amgen v. Sanofi is the most important patent-claiming decision of the decade for the life sciences, and its lesson is discipline in scope. Broad functional claims—claims that define an invention by what it does rather than what it is—are now far more vulnerable, especially in unpredictable arts like antibody biology where small structural changes have unpredictable functional effects. A patentee that wants durable protection must either disclose enough structural diversity to genuinely enable the breadth it claims, or claim more narrowly around the specific embodiments it has actually made and characterized. The strategic tension is real: narrow claims are easier to design around, but broad claims may not survive a Section 112 challenge. After Amgen, the prudent course in biotech is layered claiming—narrow, robustly enabled claims as the reliable core, supported by broader claims only where the disclosure can genuinely carry them.

Hypothetical: Borealis Labs discovers an antibody that binds a newly identified cancer-cell receptor and wants the broadest possible patent. If it claims "any antibody that binds receptor X and inhibits tumor growth," disclosing only the dozen antibodies it actually made, it risks Amgen-style invalidation the moment a competitor with a structurally different antibody challenges the claim. If instead Borealis files a tiered portfolio—narrow claims to the specific sequences it characterized, intermediate claims to defined structural families it can show it enabled, and broad functional claims only where its data support them—it preserves a defensible core even if the outer ring falls. The art is in the layering, and it is built during prosecution, not litigation.

The decision also reverberates into prosecution practice. As the firm discusses in its guidance on responding to patent office actions and preparing an invention disclosure, the time to build an enablement record is during prosecution—generating and disclosing structural diversity, working examples, and predictable structure-function relationships—not after a court has put the breadth of your claims on trial.

Case Study 8: CRISPR and the Broad–UC Interference

What Happened

The final case study reaches into the future of medicine. CRISPR-Cas9 is a revolutionary gene-editing technology that lets scientists cut and edit DNA with unprecedented precision—a tool with applications from agriculture to curing genetic disease, and the subject of the 2020 Nobel Prize in Chemistry awarded to Jennifer Doudna and Emmanuelle Charpentier. The patent question was simple to state and enormously consequential: who invented the right to use CRISPR in eukaryotic cells—the cells of plants, animals, and humans, which is where the medical and agricultural value lies?

Two camps claimed it. The University of California (with Berkeley's Doudna and Vienna's Charpentier) published foundational work in 2012 showing CRISPR-Cas9 cutting DNA in a test-tube (cell-free) environment and filed first. The Broad Institute (affiliated with MIT and Harvard, with researcher Feng Zhang) filed later but demonstrated CRISPR working specifically in eukaryotic cells, and—by paying for expedited examination—obtained issued patents first. The collision was inevitable.

The Legal Issue

Because the key applications were filed under the pre-America Invents Act "first-to-invent" system, the dispute was resolved through a patent interference—an adversarial proceeding before the PTAB to determine which party was the first true inventor of overlapping subject matter, a procedure now largely abolished for newer applications under the first-inventor-to-file system the AIA installed. The central legal question was framed as obviousness under 35 U.S.C. § 103: UC argued that once it had shown CRISPR-Cas9 working in a test tube, applying it in eukaryotic cells was an obvious next step that any skilled scientist would have achieved, so UC's earlier invention encompassed the eukaryotic use. Broad argued the opposite—that getting CRISPR to function inside the complex environment of a eukaryotic cell was not obvious at all, that many in the field doubted it would work, and that Broad's success was a genuine, separately patentable invention.

The Outcome

The PTAB, and then the Federal Circuit in Regents of the University of California v. Broad Institute, Inc., 903 F.3d 1286 (Fed. Cir. 2018), sided with Broad. The tribunals held there was no interference-in-fact: UC's claims to CRISPR generally and Broad's claims to CRISPR in eukaryotic cells were separately patentable because applying the system in eukaryotic cells was not obvious in light of UC's earlier test-tube work. The Federal Circuit pointed to substantial evidence of contemporaneous skepticism—statements by scientists, including from the UC camp itself, expressing uncertainty about whether the system would function in eukaryotic cells—as proof that success was not a foregone conclusion. A later interference reaffirmed Broad's priority on the eukaryotic claims. The upshot is a split landscape: UC holds broad foundational patents on CRISPR-Cas9, while Broad holds key patents on its use in the eukaryotic cells where most therapeutic and agricultural value resides.

The Strategic Takeaway

The CRISPR interference offers several lessons that transcend gene editing. The first is procedural and is, in a sense, the oldest lesson in patent law: priority and prosecution speed matter. Broad's decision to pay for accelerated examination—getting to issuance first—shaped the entire procedural posture of the dispute and forced UC into the role of challenger. The second lesson concerns obviousness, the doctrine at the heart of so many validity fights: contemporaneous skepticism in the field, an "objective indicium" of non-obviousness that traces back to Graham v. John Deere Co., 383 U.S. 1 (1966), is powerful evidence that an advance was not obvious. The very statements scientists made expressing doubt that CRISPR would work in eukaryotic cells became the evidentiary backbone of Broad's victory. Inventors and counsel should preserve the record of how uncertain a result seemed before it succeeded, because that record can later defeat a hindsight-driven obviousness attack. (Our guide to overcoming obviousness rejections under Section 103 develops this point for prosecution practice.)

The third lesson is about the foundational technology problem. When a platform technology has many downstream applications, the patent rights may fracture—one party owning the core, another owning the most valuable application—so that no one can practice the commercially important embodiment without licenses from both. The practical consequence is a complex web of cross-licenses, exclusive field-of-use licenses to commercial spin-outs, and ongoing disputes over who must license whom. For any company built on a platform invention, the CRISPR story is a warning to think early and carefully about how foundational and application-layer rights will be allocated—including through employee invention assignment agreements and well-drafted institutional IP policies—because the answer determines who captures the value.

Synthesis: What the Wars Teach

Eight conflicts, fought across consumer electronics, telecommunications, and the life sciences, converge on a set of durable principles.

Forum selection is the master strategy, not a detail. From the divergent national outcomes in Apple-Samsung, to the German and Chinese injunctions that pressured Apple in the Qualcomm fight, to the UK Supreme Court's willingness in Unwired Planet to set a global rate, to the NPE migration to the ITC after eBay and the venue contraction after TC Heartland—the single most consequential decision in a patent war is usually where to fight. Each forum offers a different mix of speed, available remedies, injunction standards, and willingness to reach beyond its borders, and the sophisticated litigant maps those differences before filing a single complaint.

Leverage comes from the credible threat to exclude. Whether through an ITC exclusion order, a German or Chinese injunction, a UPC injunction spanning a continent, or the in-the-money settlement value of a biopharma thicket, the party that can credibly threaten to shut a product out of a market controls the negotiation. The doctrines that limit that threat—eBay in U.S. district courts, the FRAND commitment in SEP cases, the Huawei v. ZTE protocol in Europe—are precisely the levers the other side pulls to neutralize it.

Validity is a weapon, not just a defense. IPR before the PTAB, Alice under Section 101, and the enablement requirement after Amgen all mean that attacking the patent itself is often the most effective response to an infringement claim, especially when you have no products to counterclaim with. The best defense in many modern patent wars is to make the asserted patent disappear.

Most wars end at the negotiating table. Apple and Samsung settled. Apple and Qualcomm settled on the courthouse steps. AbbVie settled with every biosimilar maker. The CRISPR landscape is being resolved through field-of-use licensing. Litigation is rarely the destination; it is the costly process by which the parties discover their relative leverage so they can price a deal. Understanding when your leverage has peaked—and being ready to settle then—is as important as understanding the law.

Claim scope is a strategic choice with real consequences. Design patents and Section 289, functional antibody claims and Section 112, foundational versus application patents in CRISPR—again and again, how broadly a company claims its invention determines both the value and the vulnerability of its rights. Claim too narrowly and competitors design around you; claim too broadly and a court invalidates you. The art is in the layering.

The negotiation record is itself evidence. In SEP disputes under Huawei v. ZTE, in U.S. FRAND contract litigation after the antitrust agencies retreated, and in any case where good faith is at issue, the documented sequence of offers, counter-offers, claim charts, and security tenders frequently decides the case. The party that treats licensing correspondence as litigation exhibits in waiting holds a decisive advantage when the dispute reaches a courtroom.

For companies operating across borders and technologies, these are not abstractions. They are the working assumptions behind every portfolio decision, every clearance opinion, and every demand letter. The firm's related resources—on global patent litigation strategies, SEP and FRAND licensing, patent infringement litigation from summary judgment through post-trial, licensing your patent from valuation to term sheet, and freedom-to-operate analysis—translate these lessons into the day-to-day practice of building and defending an IP position.

Frequently Asked Questions

Why did Apple's billion-dollar design patent verdict against Samsung shrink? The largest reduction stemmed from the Supreme Court's ruling in Samsung Electronics Co. v. Apple Inc., 580 U.S. 53 (2016), that the "article of manufacture" under the design patent damages statute, 35 U.S.C. § 289, need not be the entire phone. Because Samsung could argue that the relevant article was only a component to which the patented design was applied, the available "total profit" recovery was far smaller than an award based on the whole device. On remand a jury applied a multi-factor analysis and the case settled in 2018.

What is the "article of manufacture" and why does it matter so much? Section 289 lets a design patent owner recover the infringer's total profit on the "article of manufacture" to which the design is applied. If that article is the entire product, the recovery can be enormous; if it is only a component, the recovery is far smaller. Samsung v. Apple held it can be either, and courts now weigh factors such as the scope of the claimed design, its prominence, whether it is conceptually distinct, and its physical relationship to the rest of the product. The companion case Curver Luxembourg v. Home Expressions, 938 F.3d 1334 (Fed. Cir. 2019), shows that how the patent itself names the article of manufacture can also limit its scope.

What is the difference between "patent holdup" and "patent holdout"? "Patent holdup" is the concern that an SEP holder, once an industry is locked into a standard, will demand royalties far above the patent's true value, exploiting market power the standard conferred—using the threat of an injunction as leverage. "Patent holdout" (or reverse holdup) is the opposite concern—that implementers will refuse to negotiate in good faith, forcing the patent holder to litigate or get nothing. U.S. enforcement policy swung from emphasizing holdup under the Obama administration (the Bosch and Google/Motorola consent orders) to emphasizing holdout under the "New Madison" DOJ. The Ninth Circuit's FTC v. Qualcomm, 969 F.3d 974 (9th Cir. 2020), largely treated FRAND disputes as matters for contract and patent law rather than antitrust.

Can a court in one country really set a worldwide patent license rate? Yes, in some forums. In Unwired Planet v. Huawei [2020] UKSC 37, the UK Supreme Court held that English courts may determine the terms of a global FRAND license and enjoin UK sales if the implementer refuses to accept those global terms. The court reasoned that the industry licenses SEP portfolios worldwide, so a realistic FRAND determination must do the same. Chinese courts have since shown a similar willingness, which is why forum selection has become an arms race in SEP litigation, complete with anti-suit injunctions and anti-anti-suit injunctions across jurisdictions.

How did Humira stay protected for years after its main patent expired? AbbVie built a "patent thicket"—a dense web of more than one hundred patents covering formulations, manufacturing methods, dosing, and specific uses—around Humira beyond the original molecule patent. Rather than litigate every patent to judgment, AbbVie used the thicket as leverage to negotiate settlements with biosimilar makers that delayed their U.S. launches until 2023, extending effective exclusivity well past the 2016 expiration of the core patent. The patent-dispute framework of the BPCIA (42 U.S.C. § 262(l)) and twelve-year regulatory exclusivity reinforced that position. Such staggered settlements must be structured with antitrust limits in mind, given FTC v. Actavis, 570 U.S. 136 (2013).

What did Amgen v. Sanofi change for biotech patents? In Amgen Inc. v. Sanofi, 598 U.S. 594 (2023), the Supreme Court invalidated broad functional antibody claims for failing the enablement requirement of 35 U.S.C. § 112(a). The Court reaffirmed that a patent claiming an entire class must enable a skilled person to make and use the whole class without undue experimentation. As a result, broad "claim by function" strategies are riskier, and biotech patentees increasingly rely on layered claims anchored to disclosed, well-characterized embodiments.

Who owns CRISPR? The rights are split. Following the PTAB interference and the Federal Circuit's decision in Regents of the University of California v. Broad Institute, Inc., 903 F.3d 1286 (Fed. Cir. 2018), the University of California holds broad foundational patents on CRISPR-Cas9 generally, while the Broad Institute holds key patents on its use in eukaryotic cells—where most therapeutic and agricultural value lies. Commercial use of CRISPR in human and animal cells therefore often requires navigating both portfolios, typically through field-of-use licenses.

What is the most practical lesson for a company facing a patent war? Treat it as a campaign, not a case. Decide where to fight before you decide whether to fight; identify whether your leverage comes from the threat to exclude or from the ability to attack validity; build a clean negotiation record from the first letter; and recognize that the goal of litigation is almost always to reach a better settlement, not a verdict.

Related Articles

Disclaimer: This article is provided by mclaw.io for general informational purposes only and does not constitute legal advice. Patent law is fact-specific and evolves rapidly; the case outcomes described here turn on their particular records and procedural postures. Reading this article does not create an attorney-client relationship. Before making decisions about patent prosecution, litigation, licensing, or cross-border enforcement, consult qualified intellectual property counsel about your specific circumstances.